Human Fibrinogen Concentrate Market By Indication (Congenital Fibrinogen Deficiency, Surgical Procedure), By Form (Lyophilized, Powder, Liquid), By End User (Hospitals, Ambulatory Surgical Centers, Others): Global Opportunity Analysis and Industry Forecast, 2024-2035
The global Human Fibrinogen Concentrate Market size was valued at $0.8 billion in 2023 and is projected to reach $2.9 billion by 2035, registering a CAGR of 11% from 2023 to 2035.
Human fibrinogen is a soluble plasma glycoprotein that plays a vital role in blood clot formation as a key clotting factor. Fibrinogen concentrate receives detailed attention for managing acute bleeding incidents in patients with bleeding disorders. This glycoprotein is used as a medicinal treatment for blood disorders in vertebrates, aids in clot formation. Human fibrinogens concentrate significantly improve the firmness of whole blood clots and reduces the need for postoperative transfusions in severely bleeding patients. Factors such as increase in use of fibrinogen concentrate for bleeding patients and congenital deficiency treatment are propelling the growth of the global market.
Human fibrinogens are currently used in several surgical specialties, including cardiovascular surgery, urological surgery, pulmonary surgery, wound management, orthopedic surgery, ophthalmic surgery, neurosurgery, plastic and reconstructive surgery, and dental surgery to reduce blood loss. Human fibrinogen is used for sealing tissue during surgery. Human fibrinogen helps in reducing blood loss and to stop blood flow during surgeries and in wound management. Human fibrinogens mimic the final steps of the physiological coagulation cascade to form a fibrin clot. Use of human fibrinogen can also reduce perioperative and postoperative complications by reducing fluid leakage, air leakage, and by preventing fistulae formation. Human fibrinogen has a unique physiologic action, and the resulting fibrin clot is fully degraded by the body's natural wound healing process.
The Human Fibrinogen Concentrate Market share has witnessed growth, owing to increase in geriatric population that are prone to chronic diseases, and rise in prevalence of diseases such as gastric diseases, heart attack, atherosclerosis disease, ischemic stroke, aneurysm, tumors, blood clot in brain, cancer, myocardial infarction, arrythmia, increases in blockages of blood vessel in heart, brain, kidney and liver is led to increase in number surgeries. Rise in sports injuries and road accidents is also increasing the demand for human fibrinogen products. Hence, all such factors boost the growth of the Human Fibrinogen Concentrate Market size.
For instance, according to health hearty 2020 report, the incident rate of heart attacks per 10,000 people is around 190 in people who are over 85 years of age, around 117 for those between 75-84 years of age. According to the National Center for Health Statistics, every year, more than 795,000 people in the U.S. have a stroke.
However, unfavorable reimbursements and complications such as high costs associated with fibrin sealant products are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for fibrin sealant manufacturers globally in the future.
Major companies operating in the market include CSL Behring GmbH, Octapharma USA, Grifols, S.A., LFB Biomedicaments, Shanghai RAAS Blood Products Co., Ltd., Takeda Pharmaceutical Company Limited, Baxter International Inc., Biotest AG, BioRad, and Harbin Pacific Biopharmaceutical Co., Ltd. Key players have adopted partnership and collaboration as their key strategy to improve the product portfolio of the Human Fibrinogen Concentrate Market.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the human fibrinogen market analysis from 2023 to 2035 to identify the prevailing human fibrinogen market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the human fibrinogen market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global human fibrinogen market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Form
Lyophilized
Powder
Liquid
By End User
Hospitals
Ambulatory Surgical Centers
Others
By Indication
Surgical Procedure
Congenital Fibrinogen Deficiency
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
CSL Limited
Grifols, S.A.
Intas Pharmaceuticals Limited
Octapharma AG
Shanghai RAAS Blood Products Co., Ltd.
The LFB group
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- CHAPTER 4: HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Congenital Fibrinogen Deficiency
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Surgical Procedure
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- CHAPTER 5: HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Lyophilized
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Powder
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.4. Liquid
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
- CHAPTER 6: HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospitals
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Ambulatory Surgical Centers
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Others
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- CHAPTER 7: HUMAN FIBRINOGEN CONCENTRATE MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Indication
- 7.2.3. Market size and forecast, by Form
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Market size and forecast, by Indication
- 7.2.5.1.2. Market size and forecast, by Form
- 7.2.5.1.3. Market size and forecast, by End User
- 7.2.5.2. Canada
- 7.2.5.2.1. Market size and forecast, by Indication
- 7.2.5.2.2. Market size and forecast, by Form
- 7.2.5.2.3. Market size and forecast, by End User
- 7.2.5.3. Mexico
- 7.2.5.3.1. Market size and forecast, by Indication
- 7.2.5.3.2. Market size and forecast, by Form
- 7.2.5.3.3. Market size and forecast, by End User
- 7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Indication
- 7.3.3. Market size and forecast, by Form
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Market size and forecast, by Indication
- 7.3.5.1.2. Market size and forecast, by Form
- 7.3.5.1.3. Market size and forecast, by End User
- 7.3.5.2. France
- 7.3.5.2.1. Market size and forecast, by Indication
- 7.3.5.2.2. Market size and forecast, by Form
- 7.3.5.2.3. Market size and forecast, by End User
- 7.3.5.3. UK
- 7.3.5.3.1. Market size and forecast, by Indication
- 7.3.5.3.2. Market size and forecast, by Form
- 7.3.5.3.3. Market size and forecast, by End User
- 7.3.5.4. Italy
- 7.3.5.4.1. Market size and forecast, by Indication
- 7.3.5.4.2. Market size and forecast, by Form
- 7.3.5.4.3. Market size and forecast, by End User
- 7.3.5.5. Spain
- 7.3.5.5.1. Market size and forecast, by Indication
- 7.3.5.5.2. Market size and forecast, by Form
- 7.3.5.5.3. Market size and forecast, by End User
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Market size and forecast, by Indication
- 7.3.5.6.2. Market size and forecast, by Form
- 7.3.5.6.3. Market size and forecast, by End User
- 7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Indication
- 7.4.3. Market size and forecast, by Form
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Market size and forecast, by Indication
- 7.4.5.1.2. Market size and forecast, by Form
- 7.4.5.1.3. Market size and forecast, by End User
- 7.4.5.2. China
- 7.4.5.2.1. Market size and forecast, by Indication
- 7.4.5.2.2. Market size and forecast, by Form
- 7.4.5.2.3. Market size and forecast, by End User
- 7.4.5.3. Australia
- 7.4.5.3.1. Market size and forecast, by Indication
- 7.4.5.3.2. Market size and forecast, by Form
- 7.4.5.3.3. Market size and forecast, by End User
- 7.4.5.4. India
- 7.4.5.4.1. Market size and forecast, by Indication
- 7.4.5.4.2. Market size and forecast, by Form
- 7.4.5.4.3. Market size and forecast, by End User
- 7.4.5.5. South Korea
- 7.4.5.5.1. Market size and forecast, by Indication
- 7.4.5.5.2. Market size and forecast, by Form
- 7.4.5.5.3. Market size and forecast, by End User
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Market size and forecast, by Indication
- 7.4.5.6.2. Market size and forecast, by Form
- 7.4.5.6.3. Market size and forecast, by End User
- 7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Indication
- 7.5.3. Market size and forecast, by Form
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Market size and forecast, by Indication
- 7.5.5.1.2. Market size and forecast, by Form
- 7.5.5.1.3. Market size and forecast, by End User
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Market size and forecast, by Indication
- 7.5.5.2.2. Market size and forecast, by Form
- 7.5.5.2.3. Market size and forecast, by End User
- 7.5.5.3. South Africa
- 7.5.5.3.1. Market size and forecast, by Indication
- 7.5.5.3.2. Market size and forecast, by Form
- 7.5.5.3.3. Market size and forecast, by End User
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Market size and forecast, by Indication
- 7.5.5.4.2. Market size and forecast, by Form
- 7.5.5.4.3. Market size and forecast, by End User
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product mapping of top 10 player
- 8.4. Competitive dashboard
- 8.5. Competitive heatmap
- 8.6. Top player positioning, 2023
- CHAPTER 9: COMPANY PROFILES
- 9.1. CSL Limited
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
- 9.2. Octapharma AG
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
- 9.3. Shanghai RAAS Blood Products Co., Ltd.
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
- 9.4. The LFB group
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
- 9.5. Grifols, S.A.
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
- 9.6. Intas Pharmaceuticals Limited
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook